Seattle biopharma raises $22 million through stock sale
Seattle-based biopharmaceutical company, the Omeros Corporation, is raising approximately $22 million via a registered direct offering.
Founded in 1994, Omeros is actively advancing its treatment pipeline, which includes therapies targeting cancer, addiction, and compulsive disorders, among others. One notable candidate is narsoplimab, which is designed to prevent inflammation and damage to the membranes lining the heart and blood vessels.
This capital infusion is poised to fuel the company’s innovation efforts in the coming quarter.